Biocartis Group NV

Biocartis Group NV is an innovative molecular diagnostics company that aims to revolutionize molecular testing with its unique proprietary IdyllaTM platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis has a market cap of about 1.2 billion euros as of May 2023.

Biocartis focuses on oncology and infectious disease testing, offering rapid, in-house biomarker testing for fast treatment decisions. The company has developed a portfolio of tests for various cancers, such as lung, colorectal, melanoma, and breast cancer. Biocartis also collaborates with pharmaceutical and diagnostic companies to develop companion diagnostics and novel biomarkers.

Biocartis has the vision to make personalized medicine accessible and actionable for everyone. The company believes that molecular diagnostics can improve clinical practice and patient outcomes by providing timely and accurate information for the diagnosis, prognosis, therapy selection, and monitoring. Biocartis is committed to advancing the future of personalized medicine with its innovative solutions.

The IdyllaTM platform is a revolutionary, fully automated system that makes molecular testing convenient and affordable. It can perform complex molecular analyses from a single cartridge using a small sample of tissue or blood. The platform delivers results in only 3 hours, compared to days or weeks for conventional methods. The IdyllaTM platform is suitable for any lab setting and does not require specialized personnel or infrastructure.

Foundation: 2007
Headquarters: Mechelen, Belgium
Website: https://www.biocartis.com/en